Can-3110 receives fda fast track designation for treatment of recurrent high-grade glioma

Needham, mass., feb. 13, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the u.s. food and drug administration (fda) granted fast track designation for can-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (hsv-1) oncolytic viral immunotherapy candidate – for the treatment of patients with recurrent high-grade glioma (hgg) to improve overall survival.
CADL Ratings Summary
CADL Quant Ranking